Abstracts

First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

Background The guidelines support the use of the epidermal growth factor receptor (EGFR) inhibitors panitumumab or cetuximab for the treatment of metastatic colorectal c...

06/27/2022

The impact of the multidisciplinary team (MDT) in the management of colorectal cancer (CRC)

Background The management of CRC is complex, particularly in metastatic disease, where it is crucial the definition of disease burden, the assessment of radiological res...

06/27/2022

Can a patient navigator increase quality of life in colorectal cancer patients? The WeGuide trial

Background An estimated one-third of patients with cancer will experience clinically significant distress, manifesting as anxiety or depression that is associated with t...

06/27/2022

Pre-surgical staging and surveillance after curative treatment for pancreatic ductal adenocarcinoma (PDAC): Survey of practice in the United Kingdom (UK)

Background Differences in pre-operative staging and surveillance after curative treatment for PDAC hamper interpretation of outcome data. Methods ...

06/27/2022

First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up

Background NIVO + chemo demonstrated a clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) vs chemotherapy alone, along with a...

06/27/2022

Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)

Background The RAISE study demonstrated the superiority of FOLFIRI plus ramucirumab (Ram) to FOLFIRI in second-line metastatic colorectal cancer (CRC) patients progresse...

06/27/2022

A phase II study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma

Background Fibroblast growth factor (FGFR) alterations occur in 10-15% adult patients with advanced cholangiocarcinoma (CCA). Pemigatinib and Infigratinib, the first gen...

06/27/2022

A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis

Background Surgical resection has been accepted as the standard therapy for colorectal cancer liver metastases (CRLM), however, high recurrence incidence even after cura...

06/27/2022

Precision oncology without biomarkers: Assessing drug sensitivity in patient-derived tumoroids to guide mCRC 3rd line therapy

Background “Precision Oncology” refers to strategies and tools to find the best treatment for a specific patient. This concept is often reduced to the combination of tar...

06/27/2022

A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study

Background FOLFOXIRI plus bevacizumab (BEV) is the standard first-line treatment for metastatic colorectal cancer (mCRC) despite its association with a high incidence of...

06/27/2022